Key Highlights

  • Third-quarter net loss was USD 51.1 million, or USD 0.74 per share, compared with USD 29.9 million, or USD 0.50 per share, a year earlier, as spending on its lead program increased.
  • Research and development expense rose to USD 43.1 million from USD 25.5 million, with USD 9.1 million of the USD 17.6 million increase from external costs and USD 8.1 million from personnel.
  • Cash, cash equivalents and marketable securities totaled USD 700.5 million at September 30, 2026, which the company said is sufficient to fund operating expenses and capital expenditures through 2030.
  • Initial results from the SURF302 bladder cancer trial showed a 79% overall response rate and a 64% complete response rate in the 60 mg cohort, based on 14 evaluable participants.

Expanding Trials Push the Quarterly Loss to USD 51.1 Million

Tyra Biosciences (NASDAQ:TYRA) filed its Quarterly Report on November 10, 2026 for the period ended September 30, 2026. The clinical-stage company develops oral precision medicines targeting FGFR biology and has no product revenue. Total operating expenses were USD 54.9 million against USD 32.9 million, and interest and other income was USD 3.8 million versus USD 3.1 million. General and administrative expense rose to USD 11.7 million from USD 7.5 million, with headcount growth lifting compensation, including USD 1.6 million more non-cash stock-based pay. For nine months, the net loss was USD 136.0 million, or USD 2.07 per share, versus USD 86.1 million, or USD 1.45.

Where the Research Money Is Going: Dabogratinib 3x3

Most of the increase went to oral dabogratinib, the lead program, which the company is advancing in three Phase 2 trials it calls its 3x3 strategy. External spending in the quarter was USD 7.3 million on SURF302 in bladder cancer, USD 5.9 million on BEACH301 in children with achondroplasia and USD 4.5 million on SURF303 in upper tract urothelial carcinoma. Spending on the earlier metastatic urothelial program fell to USD 0.3 million from USD 2.7 million. In SURF302, grade 3 treatment-related adverse events occurred in 2 of 44 participants, both at the 50 mg dose. The company said all responses are subject to change with continued treatment and follow-up. Further SURF303 results are expected in 2027.

Balance Sheet Built Through Equity Sales and the 2030 Runway

Total stockholders' equity was USD 692.8 million at September 30, 2026, up from USD 259.2 million at December 31, 2025, and shares outstanding rose to 68.98 million from 53.71 million. The filing says funding came mainly from sales of common stock and pre-funded warrants, which is also why interest income rose even as the company burned cash. Accumulated Deficit reached USD 507.2 million. The company said it expects to keep incurring significant and increasing losses and may need further capital if plans change. It plans to engage health authorities on Phase 3 design and expects to start a registrational adjuvant study in 2027, subject to that feedback.

Where Things Stand

The loss is the cost of running three dabogratinib trials at once, not a sign of trouble in the filing. Tyra Biosciences (NASDAQ:TYRA) lost USD 51.1 million because research spending rose USD 17.6 million, while USD 700.5 million of cash and securities is, by the company's own estimate, enough to fund operations through 2030. The open questions are clinical: the early bladder cancer response data are from small cohorts and can change, and pediatric and upper tract data are due in 2027. Next markers are the 70 mg cohort, health authority feedback and the planned 2027 registrational study start.